Terray Therapeutics Announced A Multi-target Collaboration Agreement With Bristol Myers Squibb To Discover And Develop Small Molecule Therapeutics In Certain Disease Areas
Portfolio Pulse from Benzinga Newsdesk
Terray Therapeutics has entered into a collaboration with Bristol Myers Squibb (BMY) to discover and develop small molecule therapeutics using Terray's tNova platform. Terray will receive an upfront payment, potential milestone payments, and royalties on net sales of products commercialized by BMY.

December 14, 2023 | 12:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bristol Myers Squibb's partnership with Terray Therapeutics could enhance its pipeline with new small molecule therapeutics and potentially lead to future revenue through commercialization.
The collaboration with Terray Therapeutics is likely to have a positive impact on BMY's stock in the short term due to the potential expansion of its therapeutic pipeline and the future revenue prospects from commercialization. The deal includes milestone payments and royalties, which are positive financial incentives. However, the actual impact will depend on the success of the compounds developed and the time frame for development and commercialization, which is typically uncertain in the pharmaceutical industry.
CONFIDENCE 75
IMPORTANCE 70
RELEVANCE 80